Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Regulatory

Biomind Labs Announces Revocation of Cease Trade Order

By The Northwire Desk — AI Analysis Nov 25, 2025 · 17:20 BMND · 0.35 BIOMIND LABS INC.
BMND · Price

Executive Summary

  • The Ontario Securities Commission revoked the cease‑trade order on Biomind Labs Inc., allowing its securities to resume trading as of November 25, 2025.
  • All outstanding continuous disclosure documents for 2024‑2025 (audited and interim financial statements, MD&A, officers’ certificates, annual information form, and executive compensation statement) have now been filed on SEDAR+.
  • The Company must hold an Annual General and Special Meeting before February 25, 2026; no material changes to its business plan have occurred, though it continues to face going‑concern uncertainties.

Key Details

  • Cease‑Trade Order Revocation: Effective November 25, 2025, the OSC lifted the order issued on April 4, 2025 due to the Company’s filing of required documents.
  • Filed Documents (available on SEDAR+):
  • Audited financial statements for FY ended December 31, 2024.
  • MD&A and officers’ certificates for FY 2024 and interim periods ending March 31, 2025; June 30, 2025; September 30, 2025.
  • Annual Information Form for FY 2024.
  • Form 51‑102F6 – Statement of Executive Compensation (FY 2024).
  • AGSM Requirement: The Company’s most recent AGSM was held on June 28, 2023; the OSC requires a new AGSM to be held before February 25, 2026. Details will be announced later.
  • Going‑Concern Disclosure: Continuous disclosure documents prepared on a going‑concern basis acknowledge material uncertainties—including ongoing operating losses and need for additional financing—that could cast significant doubt on the Company’s ability to continue operations.
  • No Material Business Changes: The Company reports no changes to its current or future business plans since the cease‑trade order was imposed.

Notable Quotes

“There have been no material changes to the Company's current and future business plans since the issuance of the FFCTO.” – Alejandro Antalich, CEO

This release is primarily a regulatory update indicating that Biomind Labs Inc. has satisfied filing obligations, resulting in the removal of trading restrictions—a materially positive development for shareholders.

Read the original news release →

More from BIOMIND LABS INC.

Apr 20, 2026 · 08:30

Biomind Labs Claims 100% Remission in Alzheimer's Depression Trial Amidst Regulatory Tailwinds

Regulatory Jan 27, 2026 · 19:54

Biomind arranges $2.52-million private placement

Financings Jan 27, 2026 · 16:15

Biomind Labs Announces CAD $2.52 Million Private Placement Financing

Financings Dec 03, 2025 · 18:07

Biomind Labs moves BMND08 into FDA pathway

Management Dec 03, 2025 · 08:30

Biomind Labs Accelerates FDA Pathway for 5-MEO-DMT Candidate BMND08 with Proprietary Nano-Formulation as Patent Observations Are Successfully Withstood

Regulatory Nov 18, 2025 · 17:35

Biomind Labs Announces Filing of Continuous Disclosure Documents and Appointment of Scott Ackerman to the Board

Regulatory